F-1/A: Aeterna Zentaris Seeks to Acquire Ceapro Inc. Through Share and Warrant Issuance

Aeterna Zentaris is issuing new warrants and common shares to facilitate the acquisition of Ceapro Inc., aiming to create a combined entity with a diversified product pipeline and stronger financial position.

Summary

• Aeterna Zentaris is filing an amendment to its registration statement for the issuance of up to 633,583 new warrants and the underlying common shares.
• The warrants are being issued to existing shareholders and warrant holders in connection with the acquisition of Ceapro Inc.
• The acquisition will be executed through a plan of arrangement, where Aeterna Zentaris will acquire all outstanding shares of Ceapro.
• Each new warrant will be exercisable for one common share at a price of $0.01, expiring three years from the issuance date.
• The exercise price is paid on a cashless basis.
• The company has applied to list the common shares issuable upon exercise of the new warrants on the TSX and has filed an initial listing application with NASDAQ.
• The transaction aims to create a combined company with a diversified product pipeline, expanded R&D capabilities, and a stronger financial position.
• The combined company is expected to have approximately C$51.4 million in unrestricted cash as of December 31, 2023, on a pro forma basis.
• Shareholders of Aeterna Zentaris and Ceapro are each expected to own approximately 50% of the combined company, assuming the exercise of all new warrants.
• The deal is expected to close as soon as practicable after the effective date of the registration statement.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, outlining the terms of the acquisition and related warrant issuance. While the acquisition is presented as beneficial, the document also acknowledges risks and uncertainties, resulting in a neutral to slightly positive sentiment.

Positives

• The acquisition is expected to create a combined company with a diversified product pipeline, reducing risk.
• The combined company will have expanded pharmaceutical research and development capabilities.
• The transaction is expected to bolster the financial strength and capital markets profile of the combined entity.
• The combined company is expected to have approximately C$51.4 million in unrestricted cash as of December 31, 2023, on a pro forma basis.
• The dual NASDAQ and TSX listing is expected to improve trading volume and capital market profile for the Combined Company.

Negatives

• There is no established public trading market for the Aeterna Zentaris New Warrants, and the company does not expect a market to develop.
• The company will not receive any proceeds from the issuance of the Aeterna Zentaris New Warrants to Shareholders and Aeterna Warrant Holders.
• Because all Aeterna Zentaris New Warrants must be exercised on a cashless basis, the company will also not receive any proceeds from the exercise of any Aeterna Zentaris New Warrants.
• The company's results for the year ending on December 31, 2023 were significantly impacted by the planned spin-off of Kenvue, showing a sales decline of approximately 49% from C$18.8 million in 2022 to C$9.6 million in 2023.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the risk factors section of the prospectus.
• The Plan of Arrangement remains subject to satisfaction or waiver of several conditions, and there is no certainty that all conditions precedent will be met.
• The market price of the Common Shares and the Ceapro Shares will fluctuate and the Exchange Ratio is fixed, so there can be no certainty with respect to the market value of the Consideration Shares that Ceapro Shareholders will receive for their Ceapro Shares under the Plan of Arrangement.
• The issuance of a significant number of Common Shares and a resulting market overhang could adversely affect the market price of the Common Shares following completion of the Plan of Arrangement.
• The company may be a passive foreign investment company, which could result in adverse tax consequences.
• The company's share price is volatile, which may result from factors outside of the company's control.

Future Outlook

The combined company expects to meet its cash needs for the twelve-month period following the date of the prospectus based on current operations.

Industry Context

The announcement relates to the biopharmaceutical industry, where companies often seek mergers and acquisitions to diversify their product pipelines and strengthen their financial positions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention Symrise AG, a global supplier of fragrances, flavors, food nutrition, and cosmetic ingredients, with whom Ceapro has a supply and distribution agreement.
• The document also mentions Kenvue, a new company formed from the planned spin-off of Johnson and Johnson's consumer division, as a major customer of Ceapro.

Management Changes

Stakeholder Impact

• Shareholders of Aeterna Zentaris and Ceapro are each expected to own approximately 50% of the combined company, assuming the exercise of all new warrants.
• The combined company is expected to have a diversified product pipeline, which may benefit customers.
• The combined company is expected to have expanded R&D capabilities, which may benefit employees.

Next Steps

• Obtain remaining regulatory approvals.
• Satisfy customary closing conditions.
• Complete the Plan of Arrangement.
• List the common shares issuable upon exercise of the new warrants on the TSX and NASDAQ.
• Delist Ceapro Shares from the TSXV.
• Apply for a decision for Ceapro to cease to be a reporting issuer under the Securities Laws of each jurisdiction of Canada in which it is a reporting issuer.

Key Dates

Keywords

Aeterna Zentaris, Ceapro, acquisition, warrants, common shares, plan of arrangement, merger, biopharmaceutical, macimorelin, pharmaceutical